复星医药丁二酸复瑞替尼胶囊注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanbang, has submitted a drug registration application for a new indication of a drug targeting ALK-positive non-small cell lung cancer, which has been accepted by the National Medical Products Administration [1] Group 1 - Fosun Pharma announced that its subsidiary Fosun Wanbang has received acceptance for a drug registration application for Dihydroartemisinin-Ruxolitinib capsules [1] - The application is specifically for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) [1]